Legal & General Group
RGLS

Legal & General Group’s Regulus Therapeutics RGLS Stock Holding History

Legal & General Group’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,956
Closed -$10.4K – 3520
2025
Q1 		$10.4K Hold
5,956
– – ﹤0.01% 3164
2024
Q4 		$9.44K Hold
5,956
– – ﹤0.01% 3262
2024
Q3 		$9.35K Hold
5,956
– – ﹤0.01% 3286
2024
Q2 		$10.6K Buy
+5,956
New +$13.8K ﹤0.01% 3286
2017
Q2 		– Sell
-100
Closed -$20K – 3374
2017
Q1 		$20K Hold
100
– – ﹤0.01% 3078
2016
Q4 		$28K Buy
100
+43
+75% +$14K ﹤0.01% 3055
2016
Q3 		$22K Hold
57
– – ﹤0.01% 2797
2016
Q2 		$19K Buy
+57
New +$40.8K ﹤0.01% 2853

Other funds holding RGLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Legal & General Group's RGLS Position: Q2 2025 in Review

Legal & General Group sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 5,956 shares — an estimated $10.4K sold.

Legal & General Group first reported a position in RGLS in Q2 2016 and held it in 8 quarters. The position peaked at $28K in Q4 2016. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

  • Legal & General Group reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 5,956 Regulus Therapeutics shares in Q2 2025, an estimated $10.4K.
  • Legal & General Group first reported a position in Regulus Therapeutics in Q2 2016 and held it in 8 quarters.
  • Legal & General Group's Regulus Therapeutics position peaked at $28K in Q4 2016.
  • 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.